Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BioLineRx Ltd has entered a strategic license agreement with Ayrmid Ltd. for its APHEXDA program, securing $10 million upfront and potential future milestones, while also receiving a $9 million equity investment from Highbridge Capital Management. The company aims to reduce operational expenses by over 70% and plans to continue its focus on developing therapies for rare diseases and oncology, anticipating significant long-term value for shareholders.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue